Critical Analysis: Idera Pharmaceuticals (IDRA) vs. Rosetta Genomics (ROSG)
Idera Pharmaceuticals (NASDAQ: IDRA) and Rosetta Genomics (NASDAQ:ROSG) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, earnings, dividends and analyst recommendations.
This table compares Idera Pharmaceuticals and Rosetta Genomics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This table compares Idera Pharmaceuticals and Rosetta Genomics’ top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Idera Pharmaceuticals||$16.20 million||23.46||-$38.38 million||($0.33)||-5.91|
|Rosetta Genomics||$9.23 million||0.37||-$16.23 million||($11.04)||-0.06|
Rosetta Genomics has lower revenue, but higher earnings than Idera Pharmaceuticals. Idera Pharmaceuticals is trading at a lower price-to-earnings ratio than Rosetta Genomics, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
24.2% of Idera Pharmaceuticals shares are held by institutional investors. Comparatively, 8.3% of Rosetta Genomics shares are held by institutional investors. 12.4% of Idera Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
This is a breakdown of recent ratings and recommmendations for Idera Pharmaceuticals and Rosetta Genomics, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Idera Pharmaceuticals currently has a consensus target price of $5.40, indicating a potential upside of 176.92%. Rosetta Genomics has a consensus target price of $3.50, indicating a potential upside of 455.56%. Given Rosetta Genomics’ higher possible upside, analysts plainly believe Rosetta Genomics is more favorable than Idera Pharmaceuticals.
Volatility & Risk
Idera Pharmaceuticals has a beta of 2.17, suggesting that its stock price is 117% more volatile than the S&P 500. Comparatively, Rosetta Genomics has a beta of 0.31, suggesting that its stock price is 69% less volatile than the S&P 500.
Idera Pharmaceuticals beats Rosetta Genomics on 7 of the 12 factors compared between the two stocks.
Idera Pharmaceuticals Company Profile
Idera Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapeutics for oncology and rare diseases. The Company utilizes two drug discovery technology platforms to design and develop drug candidates, which include Toll-like receptor (TLR) targeting technology and third-generation antisense (3GA) technology. Using TLR technology, the Company designs synthetic oligonucleotide-based drug candidates to act by modulating the activity of specific TLRs. Using its 3GA technology, the Company is developing drug candidates to turn off the messenger ribo nucleic acid (mRNA) associated with disease causing genes. The Company’s drug candidates include IMO-8400, IMO-2125 and IMO-9200. The Company has designed TLR antagonists and agonists to act by modulating the activity of targeted TLRs. It is developing its 3GA technology to turn off the mRNA associated with disease causing genes.
Rosetta Genomics Company Profile
Rosetta Genomics Ltd. is engaged in developing and commercializing new diagnostic tests based on various genomics markers, including deoxyribonucleic acid (DNA), micro ribonucleic acid (microRNA) and protein biomarkers and using various technologies, including, Quantitative polymerase chain reaction (qPCR), microarrays, Next Generation Sequencing (NGS) and Fluorescence In Situ Hybridization (FISH). It is marketing and selling over four diagnostic tests based on its microRNA technologies, which include RosettaGX Cancer Origin, mi-LUNG, mi-KIDNEY and RosettaGX Reveal. Its therapeutic pipeline consists of the projects, which include Rimonim Consortium and Magneton Project. It focuses on developing diagnostic assay, RosettaGX Reveal V2. It is also focusing on developing Bladder cancer risk stratification. Its PersonalizeDx is focused on the detection of genomic changes through FISH technology, which helps to detect cancer.
Receive News & Ratings for Idera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Idera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.